DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine

Journal Article · · Vaccine

The M protein of group A streptococci (Strep A) is a major virulence determinant and protective antigen. The N-terminal region of the M protein is variable in sequence, defines the M/emm type, and contains epitopes that elicit opsonic antibodies that protect animals from challenge infections. Although there are >200 M types of Strep A, there is now evidence that structurally related M proteins can be grouped into clusters and that immunity may be cluster-specific in addition to M type-specific. This observation has led to recent studies of structure-based design of multivalent M peptide vaccines to select peptides predicted to cross-react with heterologous M types to improve vaccine coverage. In the current study, we have applied a refined series of peptide structural algorithms to predict immunological cross-reactivity among 117N-terminal M peptides representing the most prevalent M types of Strep A. Based on the results of the structural analyses, in combination with global M type prevalence data, we constructed a 32-valent vaccine containing 19 cross-reactive vaccine candidates predicted to cross-react with 37 heterologous M peptides to which were added 13 type-specific M peptides. Further, the 4-protein recombinant vaccine was immunogenic in rabbits and elicited significant levels of antibodies against 31/32 (97%) vaccine peptides and 28/37 (76%) peptides predicted to cross-react. The vaccine antisera also promoted opsonophagocytic killing of vaccine and cross-reactive M types of Strep A. Based on a recent analysis of M type prevalence of Strep A, the potential global coverage of the 32-valent vaccine is ~90%, ranging from 68% in Africa to 95% in North America. Our results indicate the utility of structure-based design that may be applied to future studies of broadly protective M peptide vaccines.

Research Organization:
Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States)
Sponsoring Organization:
National Institutes of Health (NIH); USDOE
Grant/Contract Number:
AC05-00OR22725
OSTI ID:
2426047
Journal Information:
Vaccine, Journal Name: Vaccine Journal Issue: 40 Vol. 41; ISSN 0264-410X
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
English

References (19)

Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments journal January 1999
The global burden of group A streptococcal diseases journal November 2005
Global emm type distribution of group A streptococci: systematic review and implications for vaccine development journal October 2009
Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes journal July 2010
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci journal October 2011
Potential coverage of a multivalent M protein-based group A streptococcal vaccine journal March 2013
Structure-based design of broadly protective group a streptococcal M protein-based vaccines journal January 2017
Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study journal February 2020
Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein–derived peptides journal March 2020
The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. journal March 1988
Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers journal October 2005
An HMM model for coiled-coil domains and a comparison with PSSM-based predictions journal April 2002
The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics journal January 2019
A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development journal May 2014
Update on group A streptococcal vaccine development journal January 2020
Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections journal May 2004
Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease journal July 2019
Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines journal August 2021
Current Knowledge of Type-Specific M Antigens of Group A Streptococci journal September 1962